FDA phases out inhaler due to environmental impact

By MATTHEW PERRONE , AP Health Writer

(AP) -- Asthma patients who rely on over-the-counter inhalers will need to switch to prescription-only alternatives as part of the federal government's latest attempt to protect the Earth's atmosphere.

The said Thursday patients who use the epinephrine inhalers to treat mild asthma will need to switch by Dec. 31 to other types that do not contain , an aerosol substance once found in a variety of spray products.

The action is part of an agreement signed by the U.S. and other nations to stop using substances that deplete the , a region in the atmosphere that helps block harmful ultraviolet rays from the Sun.

But the switch to a greener inhaler will cost consumers more. Epinephrine inhalers are available via online retailers for around $20, whereas the alternatives, which contain the drug albuterol, range from $30 to $60.

The FDA finalized plans to phase out the products in 2008 and currently only Armstrong Pharmaceutical's Primatene mist is available in the U.S. Other manufacturers have switched to an environmentally-friendly propellant called hydrofluoroalkane. Both types of inhalers offer quick-relief to symptoms like shortness of breath and chest tightness, but the environmentally-friendly inhalers are only available via prescription.

"If you rely on an over-the-counter inhaler to relieve your , it is important that you contact a health care professional to talk about switching to a different medicine to treat your asthma," said Badrul Chowdhury, FDA's director of pulmonary drug division.

Chowdhury told reporters and doctors via teleconference that "in the worst case scenario we are looking at 1 to 2 million people using" Primatene, adding that most of those patients likely use multiple medications to treat their asthma.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Nano-particle research will benefit inhaler-users

Apr 29, 2005

Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers. Scientists in the Welsh School of ...

Pharmacists as educators can improve asthma outcomes

Jun 24, 2008

New research has shown that up to 90 per cent of people on asthma medications are using their inhalers incorrectly leading to poor asthma control, increased hospital visits and increased cost of treatment.

Mold linked to asthma

Sep 05, 2007

A Cardiff University study has found that removing indoor mold improves the symptoms of people with asthma.

Recommended for you

FDA reconsiders behavior-modifying 'shock devices'

4 hours ago

(HealthDay)—They're likened to a dog's "shock collar" by some and called a "life-saving treatment" by others. But the days of electro-shock devices as a tool for managing hard-to-control behavior in people ...

FDA proposes accelerated medical device approval plan

Apr 23, 2014

(HealthDay)—The U.S. Food and Drug Administration has proposed a new program that would provide expedited access to high-risk medical devices intended for patients with serious conditions whose medical ...

Targeting drugs to reduce side effects

Apr 23, 2014

(Medical Xpress)—Consider ice cream – the base of which is frozen cream. Ingredients are then added to make different flavours. All these flavours are distinctly different but are created from the same foundation.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Jesse_EngAmer
not rated yet Sep 23, 2011
This wouldn't be the first time the FDA's priorities didn't align with the American publics. More and more the FDA seems to exist solely to serve big pharma. Remember Vioxx? Just look up Dr. Graham, FDA official turned whistleblower. He went public after the FDA fired him for exposing the dangers of Vioxx. He was told by his boss that the public was not the FDAs client. Industry was. http://www.youtub...Axocz1X4

1-2 Million people are going be forced to switch medication. Not only do not all medications work for everybody but as the article states not every will be able to afford the switch. Where have the FDA's priorities and values gone?